FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

Near­ly 11 years ago, sci­en­tists pro­grammed a pair of mol­e­c­u­lar scis­sors to make pre­cise cuts in DNA. That first test tube ex­per­i­ment of CRISPR gene edit­ing tech­nol­o­gy won its cre­ators a No­bel Prize, ig­nit­ed a gene edit­ing rev­o­lu­tion in life sci­ence labs, and kick-start­ed a race to de­vel­op gene-al­ter­ing med­i­cines.

Now, the fin­ish line is in sight. For the first time, a CRISPR ther­a­py is up for FDA ap­proval, Ver­tex and CRISPR Ther­a­peu­tics an­nounced Thurs­day evening.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA